A Feasibility study of quantitative molecular characterization of musculoskeletal lesions by proton MR spectroscopy at 3 T

American Journal of Roentgenology

Volumn 195, Issue 1, 2010, Pages

  Fayad, Laura M ^a   Wang, Xin ^a   Salibi, Nouha ^b   Barker, Peter B ^a   Jacobs, Michael A ^c   Machado, Antonio J ^a   Weber, Kristy L ^c   Bluemke, David A ^d  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b MR Spectroscopy   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Bone mass; MR spectroscopy; MRI; Musculoskeletal neoplasm; Soft tissue mass

Indexed keywords

CHOLINE; WATER; BIOLOGICAL MARKER; CONTRAST MEDIUM; PROTON;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BONE CYST; BONE LESION; CHORDOMA; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DESMOID TUMOR; ENCHONDROMA; EWING SARCOMA; FEASIBILITY STUDY; FEMALE; FIBROSIS; FOLLOW UP; GANGLION; GIANT CELL TUMOR; HEMATOMA; HISTOPATHOLOGY; HUMAN; LIPOMA; MALE; MYXOSARCOMA; NEURILEMOMA; NEUROFIBROMA; PIGMENTED VILLONODULAR SYNOVITIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; RANK SUM TEST; SARCOMA; SYNOVITIS; THREE DIMENSIONAL IMAGING; ALGORITHM; COMPUTER ASSISTED DIAGNOSIS; METHODOLOGY; MIDDLE AGED; MUSCLE TUMOR; MUSCULOSKELETAL DISEASE; NONPARAMETRIC TEST; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PREDICTION AND FORECASTING;

ADULT; ALGORITHMS; BIOLOGICAL MARKERS; CHOLINE; CONTRAST MEDIA; FEASIBILITY STUDIES; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; MUSCULOSKELETAL DISEASES; PREDICTIVE VALUE OF TESTS; PROTONS; STATISTICS, NONPARAMETRIC;

EID: 77954725926     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.09.3718     Document Type: Article

References (24)

1. Berquist TH, Ehman RL, King BF, Hodgman CG, Ilstrup DM. Value of MR imaging in differentiating benign from malignant soft-tissue masses: study of 95 lesions. AJR 1990; 155:1251-1255
2. Crim JR, Seeger LL, Yao L, Chandnani V, Eckardt JJ. Diagnosis of soft-tissue masses with MR imaging: can benign masses be differentiated from malignant ones? Radiology 1992; 185:581-586
3. Oya N, Aoki J, Shinozaki T, Watanabe H, Takagishi K, Endo K. Preliminary study of proton magnetic resonance spectroscopy in bone and soft tissue tumors: an unassigned signal at 2.0-2.1 ppm may be a possible indicator of malignant neuroectodermal tumor. Radiat Med 2000; 18: 193-198
4. 1H MR spectroscopy: initial results. Radiology 2004; 232:599-605
5. Sah PL, Sharma R, Kandpal H, et al. In vivo proton spectroscopy of giant cell tumor of the bone. AJR 2008; 190:433; [web]:W133-W139
6. Fayad LM, Bluemke DA, McCarthy EF, Weber KL, Barker PB, Jacobs MA. Musculoskeletal tumors: use of proton MR spectroscopic imaging for characterization. J Magn Reson Imaging 2006; 23:23-28
7. Fayad LM, Barker PB, Jacobs MA, Weber KL, Bluemke DA. Characterization of musculoskeletal lesions on 3-T proton MR spectroscopy. AJR 2007; 188:1513-1520
8. 1H MR spectroscopy in bone and soft tissue tumors. Chin Med J (Engl) 2009; 122:39-43
9. Hsieh TJ, Li CW, Chuang HY, Liu GC, Wang CK. Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: an initial experience. J Comput Assist Tomogr 2008; 32:987-994
10. Bottomley PA, Lee Y, Weiss RG. Total creatine in muscle: imaging and quantification with proton MR spectroscopy. Radiology 1997; 204:403-410 (Pubitemid 27337486)
11. 1H chemical shift imaging reveals loss of brain tumor choline signal after administration of Gd-contrast. Magn Reson Med 1997; 37:222-225
12. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997; 129:35-43 (Pubitemid 127454051)
13. Naressi A, Couturier C, Devos JM, et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA 2001; 12:141-152
14. 1H MR spectroscopy. Magn Reson Med 2003; 50:1134-1143
15. 1H MR spectroscopy using water as an internal reference at 1.5 T. MAGMA 2006; 19:96-104
16. Soher BJ, Hurd RE, Sailasuta N, Barker PB. Quantitation of automated single-voxel proton MRS using cerebral water as an internal reference. Magn Reson Med 1996; 36:335-339
17. Fayad LM, Salibi N, Wang X, et al. Quantification of muscle choline concentration by proton MR spectroscopy at 3 T: technical feasibility. AJR 2010; 194:228; [web]:W73-W79
18. 1H MRS and dynamic contrast-enhanced MRI of human breast cancer. Magn Reson Imaging 2008; 26:523-531
19. Tong Z, Yamaki T, Harada K, Houkin K. In vivo quantification of the metabolites in normal brain and brain tumors by proton MR spectroscopy using water as an internal standard. Magn Reson Imaging 2004; 22:735-742
20. Biondetti PR, Ehman RL. Soft-tissue sarcomas: use of textural patterns in skeletal muscle as a diagnostic feature in postoperative MR imaging. Radiology 1992; 183:845-848
21. Vanel D, Lacombe MJ, Coanet D, Kalifa C, Spielmann M, Genin J. Musculoskeletal tumors: follow-up with MR imaging after treatment with surgery and radiation therapy. Radiology 1987; 164:243-245 (Pubitemid 17089912)
22. Reuther G, Mutscheler W. Detection of local recurrent disease in musculoskeletal tumors: magnetic resonance imaging versus computed tomography. Skeletal Radiol 1990; 19:85-89
23. De Schepper AM, De Beuckeleer L, Vandevenne J, Somville J. Magnetic resonance imaging of soft tissue tumors. Eur Radiol 2000; 10:213-222 (Pubitemid 30136821)
24. 1H MR spectroscopy of the brain: absolute quantification of metabolites. Radiology 2006; 240:318-332